About IAC
A-Z Index
Immunization Action Coalition
IAC Home
Ask the Experts

Ask the Experts

Experts from the CDC Answer Questions About Vaccines

Vaccine Index
Topic index
View All
Meet the Experts
From the National Center for Immunization and Respiratory Diseases at CDC, introducing
Medical Officer Andrew T. Kroger, MD, MPH
Nurse Educator Donna L. Weaver, RN, MN
Submit a Question: Ask the Experts
You can email your question about vaccines or immunization to IAC. We will respond to your email inquiry.
Related Materials from IAC
IAC Express
Needle Tips
Vaccinate Adults
What's New - Q&As
Love the Question of the Week?
Receive it every week in your email box
>> Subscribe to IAC Express!
QUESTION: With the ACIP recommendation to not use live attenuated influenza vaccine (LAIV, FluMist, AstraZeneca) during the 20162017 season will there be enough inactivated influenza vaccine (IIV) to meet the demand for the upcoming season?
ANSWER: Influenza vaccine manufacturers project that as many as 171 to 176 million doses of influenza vaccine will be available for the 20162017 season. LAIV accounts for up to 14 million of those doses (about 8% of the total supply). Based on manufacturer projections, health officials expect that supply of IIV for the 20162017 season should be sufficient to meet any increase in demand resulting from the ACIP recommendation, though providers may need to check more than one supplier or purchase a vaccine brand other than the one they normally select.
Question of the Week Archive
Immunization Action Coalition  •  2550 University Avenue West  •  Suite 415 North  •  Saint Paul, Minnesota  •  55114
tel 651-647-9009  •  fax 651-647-9131
This website is supported in part by a cooperative agreement from the National Center for Immunization and Respiratory Diseases (Grant No. 5U38IP000589) at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. The website content is the sole responsibility of IAC and does not necessarily represent the official views of CDC.